These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26303705)

  • 1. Nuclear Medicine Imaging of Neuroendocrine Tumors.
    Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
    Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
    Kjaer A; Knigge U
    Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
    Cuccurullo V; Di Stasio GD; Mansi L
    Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel PET tracers: added value for endocrine disorders.
    Bergeret S; Charbit J; Ansquer C; Bera G; Chanson P; Lussey-Lepoutre C
    Endocrine; 2019 Apr; 64(1):14-30. PubMed ID: 30875057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
    Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary nuclear medicine imaging of neuroendocrine tumours.
    Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
    Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
    Johnbeck CB; Knigge U; Kjær A
    Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
    Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
    J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
    Li S; Beheshti M
    Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Kim MK; Rinke A; Bergestuen DS; Thirlwell C; Khan MS; Salazar R; Oberg K
    Neuroendocrinology; 2014; 99(2):63-74. PubMed ID: 24458014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear medicine in NET.
    Sorschag M; Malle P; Gallowitsch HJ
    Wien Med Wochenschr; 2012 Oct; 162(19-20):416-22. PubMed ID: 22810487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
    Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
    J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
    Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
    Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.